Karin Melsens, Els Vandecasteele, Ellen Deschepper, Valérie Badot, Daniel Blockmans, Guy Brusselle, Ellen De Langhe, Michel De Pauw, Claire Debusschere, Saskia Decuman, Liselotte Deroo, Frédéric Houssiau, Jan Lenaerts, Yves Piette, Kristof Thevissen, Marie Vanthuyne, René Westhovens, Sara Wijnant, Filip De Keyser, Vanessa Smith
Objectives: Following results in open-label studies of rituximab in patients with systemic sclerosis, a Belgian three-centre initiative was launched to explore safety and efficacy of rituximab in early, diffuse cutaneous systemic sclerosis (dcSSc). Methods: Open-label study of 17 patients with early dcSSc, treated with two courses of rituximab, at month 0 and 6. Clinical examination, lung function testing, echocardiography, disease activity score (DAS) and functional status were performed at baseline and over 24 months of follow-up. Results: Modified Rodnan skin score (MRSS) changed significantly over time, with a mean of 25.5 (standard deviation [SD] 6.0) at baseline to 12.6 (SD 5.1) at month 24 (Mixed Model Analysis [MMA] p
Melsens, K, Vandecasteele, E, Deschepper, E, Badot, V, Blockmans, D, Brusselle, G, De Langhe, E, De Pauw, M, Debusschere, C, Decuman, S, Deroo, L, Houssiau, F, Lenaerts, J, Piette, Y, Thevissen, K, Vanthuyne, M, Westhovens, R, Wijnant, S, De Keyser, F & Smith, V 2018, 'Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis', Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine, vol. 73, no. 2, pp. 119-125. https://doi.org/10.1080/17843286.2017.1372244
Melsens, K., Vandecasteele, E., Deschepper, E., Badot, V., Blockmans, D., Brusselle, G., De Langhe, E., De Pauw, M., Debusschere, C., Decuman, S., Deroo, L., Houssiau, F., Lenaerts, J., Piette, Y., Thevissen, K., Vanthuyne, M., Westhovens, R., Wijnant, S., De Keyser, F., & Smith, V. (2018). Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine, 73(2), 119-125. https://doi.org/10.1080/17843286.2017.1372244
@article{99db57f880fe43b489ba8eac4773d45d,
title = "Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis",
abstract = "Objectives: Following results in open-label studies of rituximab in patients with systemic sclerosis, a Belgian three-centre initiative was launched to explore safety and efficacy of rituximab in early, diffuse cutaneous systemic sclerosis (dcSSc). Methods: Open-label study of 17 patients with early dcSSc, treated with two courses of rituximab, at month 0 and 6. Clinical examination, lung function testing, echocardiography, disease activity score (DAS) and functional status were performed at baseline and over 24 months of follow-up. Results: Modified Rodnan skin score (MRSS) changed significantly over time, with a mean of 25.5 (standard deviation [SD] 6.0) at baseline to 12.6 (SD 5.1) at month 24 (Mixed Model Analysis [MMA] p ",
keywords = "Systemic sclerosis, anti-CD20 therapy, clinical outcome, clinical trial, early severe diffuse scleroderma, rituximab",
author = "Karin Melsens and Els Vandecasteele and Ellen Deschepper and Val{\'e}rie Badot and Daniel Blockmans and Guy Brusselle and {De Langhe}, Ellen and {De Pauw}, Michel and Claire Debusschere and Saskia Decuman and Liselotte Deroo and Fr{\'e}d{\'e}ric Houssiau and Jan Lenaerts and Yves Piette and Kristof Thevissen and Marie Vanthuyne and Ren{\'e} Westhovens and Sara Wijnant and {De Keyser}, Filip and Vanessa Smith",
year = "2018",
month = mar,
day = "4",
doi = "10.1080/17843286.2017.1372244",
language = "English",
volume = "73",
pages = "119--125",
journal = "Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine",
issn = "1784-3286",
publisher = "Acta Clinica Belgica",
number = "2",
}